Tag: LLY

GLP-1 therapies are rapidly transforming diabetes and weight-loss treatment, new research suggests they could also weaken cancer growth, and Eli Lilly (NYSE:LLY)’s tirzepatide stands to gain if these findings hold up. In a recent mouse experiment, scientists gave obese animals tirzepatide—Lilly’s blockbuster obesity and diabetes drug—and watched not only a roughly 20% drop in body Read more